Chickens represent a specific case in lipid metabolism that liver is the main site of lipid synthesis. As ovipara, their gut microbiota could be strongly influenced by environment and diets after hatching. The aim of this study is to elucidate the linkage of gut microbiota and fat synthesis in broilers. The broilers were subjected to dietary treatments of combined probiotics (Clostridium butyrate 4×10 The hepatic lipogenesis regulated by the intestinal microbiota of chickens is of great significance to the study of intestinal microbiota and fat deposition in poultry, and this work could provide reference for intestinal microorganism and fat metabolism in mammals and humans.
CO2 for 72 h. The medium was changed at 2 days intervals.
The heptocytes were treated with 100nM chicken GLP-1 (chick GLP-1 sequence:
HAEGTYTSDITSYLEGQAAKEFIAWLVNGRG, 42), synthesized by Mimotopes, Hangzhou, China) for 24h in the present of 200µM palmitic acid in the medium. As GLP-1 is easily to be degraded, the heptocytes were treated with 100nM LG (Selleck， Houston,TX, USA) with or without the presence of 100nM exendin(Beyotime, Shanghai, China), the inhibitor of GLP-1R. The cells were harvested for further analysis.
TG and TCH content measurements
Triglyceride and total cholesterol content was determined with commercial kits (GPO-PAP and CHOD-PAP, Nanjing Jiancheng Biotechnology Institute, Nanjing, China).
Histological staining
Paraffin-embedded liver and abdominal adipose tissues were sliced into 5 μm sections for hematoxylin and eosin stain (HE, Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The histological features were observed and captured under a light microscope.
Measurement of SCFA concents
SCFA concentrations were determined using GC-MS assay. Cecal chyme was added to 2 mL of water with phosphoric acid, vortexed and homogenized for 2 min.
Then, 2 mL of ether was added to the sample, which was rested for 10 min and centrifuged at 4000 rpm for 20 min at 4 °C. The ether phase was removed after centrifugation, and then the extraction was repeated. The two extracts were combined, volatilized to 2 mL, and injected into the GCMS ISQ LT (Thermo Fisher, USA) and TRACE GCMS ISQ LT (Thermo Finnigan, USA) with the following conditions: 
Cell viability
The cell viability under different treatments was determined by CCK-8 kit (Trans, China) at the wavelength of 450nm.
Oil Red O Staining
Cells were washed with cold phosphate buffered saline (PBS) and fixed in 10% paraformaldehyde for 30 min. Then the cells were stained for 30 min in a freshly diluted Oil Red O solution (Solarbio, Beijing, China). After rinsed in distilled water, the cells were counterstained for 2 min in Mayer's Hematoxylin (Sigma-Aldrich, St.
Louis, MO, USA).The image of each group was photographed. Subsequently, the stained lipid droplets were extracted with isopropanol for quantification by measuring its absorbance at 490 nm.
RNA isolation and quantitative real-time PCR analysis
Total RNA from cultured cells or intestinal tract, including the duodenum, jejunum, ileum, cecum and colorectum, liver and abdominal adipose was prepared by the acid phenol method using Trizol reagent (Invitrogen, USA) according to the manufacturer's instructions. And 1.0 μg total RNA was reverse-transcribed into cDNA using the transcriptor first-strand cDNA synthesis kit (Roche, China). qPCR was conducted using FastStart Universal SYBR Green Master (Rox) reagents (Roche). All the primers were designed by Primer 5, and standard curves and melting curves were performed to ensure the specificity and PCR efficiency. Relative mRNA expression of the target genes was evaluated using the comparative threshold cycle method (2
−ΔΔCT
).
Each sample was amplified in triplicate, and GADPH was used as an internal control.
Primers used for qRT-PCR were listed in Table 2 . Thermal cycling was initiated with an activation step of 30s at 95°C, and this step was followed by 40 cycles of 95°C for 5s and 60°C for 30s.
Western blot analysis
Total protein extracts from cultured cell lysates or tissue samples were prepared by homogenization in RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate in PBS) supplemented with protease inhibitor cocktail (Sigma-Aldrich, Oakville, Ontario, Canada) and phosphatase inhibitor cocktail (Fdbio science, China, Alkaline phosphatases, Acid phosphatases, Alkaline phosphatases, PTPs, Ser/Thr phosphatases, PP1, PP2A,PP2B, and PP2C). Cell and tissue homogenates were centrifuged at 12,000×g and 4°C for 10 min. The protein content of the supernatants was determined using the BCA protein assaykit (Beyotime). Total protein (30 μg) was separated by SDS-PAGE and transferred to PVDF membranes (Millipore,Merck, Germany) using a transfer apparatus (BioRad, USA). The membranes were blocked with blocking buffer (Beyotime) at room temperature for 1 h, then incubated with anti-phospho-P38 (#4511T, anti-rabbit, Cell Signaling Technology (CST), USA) , anti-P38 (#9212S, anti-rabbit, CST), anti-phospho-JNK (#4668S, anti-rabbit, CST), anti-JNK (#928, anti-rabbit, CST), anti-phospho-ERK (#9101S, anti-rabbit, CST), and anti-ERK (#9102S, anti-rabbit, CST), anti-p-ACC (anti-rabbit, CST), anti-ACC (anti-rabbit, CST), anti-p-AMPK (anti-rabbit, CST) and anti-AMPK (anti-rabbit, CST) primary antibodies overnight at 4°C, followed by incubation with the corresponding horseradish peroxidase-conjugated secondary antibody (Beyotime, Shanghai, China) at 4°C for 4h. Tubulin was used as an internal control for MAPK pathway assay, and β-actin was used as an internal control for other protein expression assays. The protein-antibody complexes were detected with the ECL Plus A and B (Beyotime, Shanghai, China), and the results were quantified using the Fusion FX software (Vilber, France).
Statistical analysis
The data were expressed as mean±SE and analyzed by one-way ANOVA with SAS software. Differences between means were evaluated using Duncan's significant difference tests.p<0.05 was considered as statistically significant.
Results

PB and GG treatments suppressed lipid synthesis and accumulation in the liver and abdominal fat tissue
The GG-chickens had the lowest plasma TG concentration while the control birds had the highest one (P<0.05, Fig. 1a ). Compared to the control, the plasma TCH content was decreased by both PB (p<0.01) and GG (p<0.05) treatments (Fig. 1b) .
Plasma activity of ALT was decreased in both PB-and GG-chickens compared to control (p<0.001) while AST was not changed (p>0.05, Fig. 1c,d ).
At d 21, the liver index was significant higher in the PB group compared with control (p<0.05, Fig. 2a ). The abdominal fat index was significant lower in GG-chickens compared to the control (p<0.05, Fig. 2b ). At d 42, compared with the control, the liver and abdominal fat index were decreased (p<0.05) by PB and GG treatments (Fig. 2a, b) . Compared to control, chickens in PB and GG groups showed decreased TG content (p<0.05, Fig. 2 c) and alleviated fatty infliltration in liver both 21 and 42 days of age (Fig. 2 d) . The hepatic TCH contents, however, was not In abdominal fat tissue, the average adipocyte size was reduced in abdominal fat padin PB-and GG-chickens compared with control (Fig 2 g ). The mRNA levels of ACC and FABP4 in GG-chickens were decreased compared to control (p<0.05, Fig   1h ) . In contrast, PB treatment increased PPARG while decreased FABP4 compared to control (p<0.05).
PB and GG treatments changed the cecal microbiota diversity
Compared to the control group, GG did not change the relative abundances of Firmicutes and Bacteroidetes at the phylum level, while PB decreased the relative abundance of Firmicutes and increased the relative abundance of Bacteroidetes. There was a decrease in the relative abundances of Proteobacteria in both PB and GG groups. The minor taxonomic groups such as Actinobacteria and Verrucomicrobia showed the same trends in PB and GG treatments. In line with that at the phylum level, minor taxonomic groups of cecal microbiota in PB and GG groups presented the same trends and showed significant differences with that in control group.
Compared with the control, the Escherichia-Shigella, Anaerotruncus, Akkermansia, Ruminococcaceae_uncultured, Subdoligranulum, Ruminococcaseae and Helicobacter presented much lower abundance in both PB and GG groups, while Bifidobacterium, Campylobacter and Lactobacillus were significantly higher in PB and GG groups.
PB and GG treatments are associated with altered cecal SCFAs concentrations
Compared to the control, cecal acetate concentrations were increased in both PB and GG groups (p<0.05, Fig. 4 
PB and GG treatments upregulated the expression of FFARs and GLP-1R
Comparing with control, the mRNA levels of FFAR2 and GLP-1R were upregulated by GG treatment in ileum, ceacum and colonrectum (p<0.05), but not in cecum (P>0.05, Fig. 4 c, d , e). Except for FFAR3 mRNA level was increased by PB treatment in ceacum (p<0.05) (Fig. 4 d) , no significant influence was observed for FFAR2, FFAR3, and GLP-1R mRNA levels in other tissues by PB treatment.
SCFAs induced GLP-1 secretion via activating MAPK pathways in IECs
Compared to the control, the expression levels of FFAR2, FFAR3, and GLP-1R 
GLP-1 and its analogue liraglutide suppressed lipid accumulation through AMPK/ACC phospharalation in primary hepatocytes
In primary hepatocytes,thelipid accumulation that stained with Oil Red O and quantitated using a spectrophotometer at 500nm and TG contents were decreased by GLP-1 treatment, compared to the control (p<0.01, Fig. 6 a,b) . Compared to the control, phosphorylation levels of AMPK and ACC were increased by GLP-1 (Fig. 7 f) . In contrast, the phosphorylation level of AMPK in exendin (9-39)+liraglutide treatment had no difference compared with control or liraglutide treatment (p<0.05). The phosphorylation level of ACC, however, was not changed by liraglutide (p>0.05) (Fig. 7 g) .
Discussion
In the present study, results showed that dietary supplementation of PB and GG changed the cecal microbiota structure and diversity, altered cecal SCFA concentrations, and suppressed fat deposition in liver and abdominal fat tissues. This study indicated that both PB and GG could change the cecal microbiota structure and diversity. In line with previous studies in human and rodents (13, 49) , the decreased proportion of phylum Firmicutes and increased proportion of phylum Bacteroidetes were observed in PB group. At the genus level, the relative abundance of Lactobacillus, Bifidobacteria and Campylobacter were increased in both PB and GG groups. Lactobacilli and Bifidobacteriawere indicated to produce SCFAs during the fermentation of carbohydrates (50, 51) . Meimandipour et al. (2010) showed that Lactobacillus salivarius and L. agilis increased propionate and butyrate contents in cecum of chickens (52). In this study, supplementation with PB and GG also leads to increased ceacal contents of acetate and butyrate, but not with propionate. This is partially in agreement with studies that Lactobacillus and Bifidobacterium increased the commensal metabolite butyrate (53).
Meanwhile, decreased hepatic and plasma TG and TCH concentrations, and reduced abdominal fat ratio were observed in PB-and GG-treated chickens. Similar effects associated with probiotics and guar gum were observed in mammals. propionate, and butyrate inhibits lipolysis and de novo lipogenesis and protects against HFD-induced obesity (19, 20, 59) . One main finding of this study is that liver is also a vital target of gut microbiota regulation on fat metabolism in chickens, in which SCFAs may be linkages.
SCFAs induce the secretion of GLP-1 via MAPK pathways
Although the intracellular mechanism is not fully understood, luminal SCFAs are expected to stimulate FFAR2 and/or FFAR3 located on the colonic L cells and induce glucagon like peptide-1(GLP-1) release in mammals (28). In the present study, the increased contents of SCFAs were accompanied with higher expression levels of FFARs and GLP-1R in chicken intestines. Hudson et al. (2012) showed that FFAR2 and FFAR3 respond to acetate and butyrate at the same level, while FFAR3 was more sensitive to propionate than FFAR2 in mouse (60) . A slightly different nature from that in mice, our results showed that both chicken FFAR2 and FFAR3 responded to propionate and butyrate, while FFAR3 was a little more sensitive than FFAR2 in vitro.
But FFAR2 was much more sensitive to acetate than FFAR3 in primary IECs. JNK can also be activated by acetate, propionate or butyrate in HEK293 cells, but has rarely been studied due to its lower activation level compared to ERK (65). It is well known that ERK is a major regulator of cell proliferation, whereas JNK and p38MAPK are involved in stress signaling and many inflammatory processes (67) . Does MAPK pathway participate in the SCFAs mediated GLP-1 secretion and involve in lipid metabolism? Our present study showed that ERK were stimulated by acetate for 3.5 fold, propionate for 3 fold, and butyrate for 2.5 fold, compared to control. In contrast, significant JNK activation was only detected under butyrate treatment. This result was in agreement with the study that ERK1/2 phosphorylation level mediated by GPR43 and GPR41 were extremely higher with over 3-4 fold to the control, while activation of JNK1/3 was weak (65). The activated p38MAPK was observed in all three SCFAs treatments, which was disagree with the work in parental HEK293 cells, where the activation of p38MAPK was weak under both FFAR2 and FFAR3 stimulators (65). Additionally, in consistent with highly activated ERK and p38MAPK under the stimulation of all three SCFAs, the GLP-1 secretions were reduced to the basal level by inhibitors of ERK1/2 and p38MAPK. In contrast, the acetate mediated GLP-1 secretion is not sensitive under the inhibitor of JNK. These fingdings suggest that ERK and p38MAPK pathways are mainly involved in SCFAs-induced GLP-1 secretion in chickens, which are different from that in mammals.
GLP-1 and its analog Liraglutide decrease hepatic fat synthesis through phosphorylation of AMPK and ACC
SCFAs have been shown to stimulate the gut hormone GLP-1 release (22), and result in a reduced body weight gain and decreased fat deposition (29, 58, 68) . Their main targets are adipose tissue. In this study, we found that both GLP-1 and liraglutide could decrease lipid accumulation in the primary cultured chicken hepatocytes, indicating liver was also a target for GLP-1. Studies demonstrate that treatment with GLP-1 improves liver histology and reduces body weight in animal models of NASH (69, 70) . It is suggested that GLP-1 reduces body weight gain and fat deposition by suppressed food intake (68, 71) . In ob/ob mice, 60 days of treatment with GLP-1R agonist significantly reduced weight gain and hepatic lipid content, suggesting that GLP-1 has a direct effect on hepatocyte fat metabolism in liver and the GLP-1-treated hepatocytes showed elevated cAMP production as well as reduced mRNA expression of genes associated with fatty acid synthesis (72) . Our study showed that GLP-1 and its analog liraglutide significantly increased the phosphorylation of AMPK and ACC (acetyl-CoA carboxylase), whereas had no effect on PPARG and carnitine palmityl transferase I (CPT1) at the protein level in chicken primary hepatocytes. AMPK plays a key role in regulating energy metabolism.
Activated AMPK can phosphorylate and inactivate ACC which leads to a decrease in fatty acid synthesis (73, 74) , as well as down-regulates transcription factors and enzymes associated with lipid metabolism, such as SREBP-1c and FAS (75, 76) . were analyzed by western blotting, relative phosphorylation levels were calculated by the ratio of pAMPK/AMPK and pACC/ACC and normalized for control. Data were presented as mean± SE; *p<0.05, **p<0.01, ***p<0.001.
